Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more
Santhera Pharmaceuticals Holding AG (SPHDF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 8.037x
Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SPHDF) has a cash flow conversion efficiency ratio of 8.037x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.60 Million) by net assets ($-2.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Santhera Pharmaceuticals Holding AG - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Santhera Pharmaceuticals Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Santhera Pharmaceuticals Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eletromidia S.A
SA:ELMD3
|
0.067x |
|
Shanghai Model Organisms Center Inc
SHG:688265
|
0.018x |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
0.023x |
|
Macmahon Holdings Limited
PINK:MCHHF
|
0.292x |
|
Arch Resources Inc
NYSE:ARCH
|
0.017x |
|
Ammo Inc
NASDAQ:POWW
|
0.014x |
|
TVZone Media Co Ltd
SHG:603721
|
0.010x |
|
SVEDBERGS DALS. B SK 125
F:Q49
|
N/A |
Annual Cash Flow Conversion Efficiency for Santhera Pharmaceuticals Holding AG (2006–2024)
The table below shows the annual cash flow conversion efficiency of Santhera Pharmaceuticals Holding AG from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $27.70 Million | $-35.53 Million | -1.283x | -262.65% |
| 2023-12-31 | $59.94 Million | $47.27 Million | 0.789x | +15.44% |
| 2022-12-31 | $-43.69 Million | $-29.84 Million | 0.683x | +102.43% |
| 2021-12-31 | $1.33 Million | $-37.36 Million | -28.132x | -510.82% |
| 2020-12-31 | $-6.35 Million | $-43.51 Million | 6.848x | +5506.63% |
| 2019-12-31 | $21.25 Million | $2.60 Million | 0.122x | +108.98% |
| 2018-12-31 | $27.83 Million | $-37.87 Million | -1.361x | -10.74% |
| 2017-12-31 | $32.26 Million | $-39.63 Million | -1.229x | -236.64% |
| 2016-12-31 | $74.35 Million | $-27.14 Million | -0.365x | -73.20% |
| 2015-12-31 | $106.25 Million | $-22.39 Million | -0.211x | +40.08% |
| 2014-12-31 | $17.24 Million | $-6.06 Million | -0.352x | +64.17% |
| 2013-12-31 | $7.11 Million | $-6.98 Million | -0.982x | -4.32% |
| 2012-12-31 | $11.73 Million | $-11.04 Million | -0.941x | -103.34% |
| 2011-12-31 | $42.98 Million | $-19.89 Million | -0.463x | -385.61% |
| 2010-12-31 | $69.63 Million | $-6.64 Million | -0.095x | +61.65% |
| 2009-12-31 | $83.51 Million | $-20.75 Million | -0.249x | +43.18% |
| 2008-12-31 | $104.47 Million | $-45.69 Million | -0.437x | -164.92% |
| 2007-12-31 | $135.51 Million | $-22.37 Million | -0.165x | -1.08% |
| 2006-12-31 | $152.05 Million | $-24.83 Million | -0.163x | -- |